FSCN1、hTERT蛋白在卵巢癌组织中的表达及其临床意义

doi:10.3969/j.issn.1671-7171.2026.01.018

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1143 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 【目的】 探讨肌动蛋白结合蛋白1(FSCN1)、人端粒酶反转录酶(hTERT)蛋白在卵巢癌组织中的表达及其临床意义。【方法】 44例卵巢癌患者为观察组,选择同期卵巢良性上皮性肿瘤患者44例为对照组。比较两组患者FSCN1、hTERT蛋白在卵巢病变组织中的表达水平,分析观察组FSCN1、hTERT蛋白表达与临床病理特征的关系。【结果】 观察组患者FSCN1、hTERT高表达率分别为70.45%、72.73%,均明显高于对照组的36.36%、31.82%(P<0.05)。观察组FSCN1、hTERT蛋白表达与患者年龄、肿瘤大小、病理类型、淋巴结转移无关(P>0.05),与FIGO分期相关(P<0.05),FIGO分期越高,患者FSCN1、hTERT蛋白表达越高。【结论】 FSCN1、hTERT在卵巢癌组织中呈高表达,其表达水平与FIGO分期有关。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	仲娣
	李鹏

关键词 ：卵巢肿瘤, 末端转移酶端粒, 基因表达

Abstract：【Objective】 To investigate the expression of fascin-1(FSCN1) and human telomerase reverse transcriptase(hTERT) in ovarian cancer and their clinical significance.【Methods】 A total of 44 patients with ovarian cancer were included as the observation group, and 44 patients with benign epithelial ovarian tumors during the same period were selected as the control group. The expression levels of FSCN1 and hTERT proteins in ovarian lesion tissues were compared between the two groups. The correlations between FSCN1 and hTERT expression and clinicopathological characteristics were analyzed in the observation group.【Results】 The high expression rates of FSCN1 and hTERT in the observation group were 70.45% and 72.73%, respectively, which were significantly higher than those in the control group(36.36% and 31.82%, respectively)(P<0.05). In the observation group, FSCN1 and hTERT expression were not associated with age, tumor size, pathological type, or lymph node metastasis(P>0.05), but were related to FIGO stage(P<0.05). Higher FIGO stages were associated with higher expression levels of FSCN1 and hTERT.【Conclusion】 FSCN1 and hTERT are highly expressed in ovarian cancer, and their expression levels are associated with FIGO stage.

Key words： Ovarian Neoplasms Telomerase Gene Expression

收稿日期: 2025-09-02

中图分类号:

R737.31

引用本文:

仲娣, 李鹏. FSCN1、hTERT蛋白在卵巢癌组织中的表达及其临床意义[J]. 医学临床研究, 2026, 43(1): 66-68.
ZHONG Di, LI Peng. Expression and Clinical Significance of FSCN1 and hTERT in Ovarian Cancer. JOURNAL OF CLINICAL RESEARCH, 2026, 43(1): 66-68.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2026.01.018 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2026/V43/I1/66

[1] 刘亚娜,郭瑞霞.卵巢癌初始治疗和复发治疗的现状[J].实用肿瘤杂志,2024,39(5):407-412.
[2] LI Z X, SHI J, ZHANG N N, et al. FSCN1 acts as a promising therapeutic target in the blockade of tumor cell motility:a review of its function, mechanism, and clinical significance[J].J Cancer,2022,13(8):2528-2539.
[3] 郝凤翔,赵彬,李然,等.肌动蛋白结合蛋白1在肿瘤中的研究进展[J].癌症进展,2024,22(11):1166-1169.
[4] 杨长香,韩自旺,张欣萍,等.老年子宫内膜癌患者miR-135a、XPO4、hTERT表达水平及临床意义[J].中国老年学杂志,2025,45(3):554-558.
[5] ROAKE C M,ARTANDI S E.Regulation of human telomerase in homeostasis and disease[J].Nat Rev Mol Cell Biol,2020,21(7):384-397.
[6] 哈尼克孜·肉孜,祖菲娅·海排提,阿比丹·吐尔汗江,等.卵巢癌组织中CEACAM-1、HDAC7表达水平与患者病理特征及预后关系[J].中国计划生育学杂志,2025,33(7):1656-1660.
[7] 张灿灿,谭志军,徐敏,等.槲皮素联合si-FSCN1对胃癌MKN45细胞增殖与侵袭和凋亡的影响[J].中国临床药理学杂志,2020,36(9):1132-1135.
[8] 赵华,李荣杰.甲状腺乳头状癌组织中FSCN1、CDKN2B表达水平及其对患者预后的影响[J].中外医学研究,2023,21(20):71-74.
[9] 胡秋平,刘红艳,刘春艳,等.食管鳞状细胞癌组织中SNAI2和FSCN1蛋白表达情况对其预后生存的影响[J].山东医药,2023,63(29):59-61.
[10] BAI W, REN J S, XIA M, et al. Targeting FSCN1 with an oral small-molecule inhibitor for treating ocular neovascularization[J].J Transl Med,2023, 21(1):555.
[11] 丁转南,黄丽珊,黄素然,等.FSCN1、eIF-4A、hMOF在卵巢癌中的表达及意义[J].疑难病杂志,2020,19(2):175-179.
[12] 刘洋,廖婧,卢又汇,等. miR-21负向调控宫颈癌HeLa细胞株中hTERT的表达[J].昆明医科大学学报,2021,42(3):23-28.
[13] 马鲲鹏,曲娜.PTEN和hTERT在喉癌中的表达及意义[J].皖南医学院学报,2025,44(1):24-28.
[14] CHEN G X,WANG S W,ZHANG Q R,et al.Circulating TERT serves as the novel diagnostic and prognostic biomarker for the resectable NSCLC[J].Cancer Cell Int,2024,24(1):420-428.